Trevena’s (TRVN) “Buy” Rating Reiterated at Cowen and Company
Trevena, Inc. (NASDAQ:TRVN)‘s stock had its “buy” rating reiterated by investment analysts at Cowen and Company in a report released on Friday. They currently have a $10.00 price objective on the biopharmaceutical company’s stock. Cowen and Company’s target price points to a potential upside of 331.03% from the stock’s current price.
Other equities analysts have also recently issued reports about the company. Needham & Company LLC lifted their target price on Trevena from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, May 15th. HC Wainwright restated a “buy” rating on shares of Trevena in a report on Monday, May 8th. Roth Capital set a $9.00 target price on Trevena and gave the stock a “buy” rating in a report on Saturday, May 6th. Oppenheimer Holdings, Inc. set a $10.00 target price on Trevena and gave the stock a “buy” rating in a report on Thursday, May 4th. Finally, Aegis reiterated a “buy” rating and set a $14.00 price target on shares of Trevena in a report on Monday, April 17th. Two investment analysts have rated the stock with a sell rating and eleven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $11.27.
Trevena (TRVN) traded up 6.90% during mid-day trading on Friday, hitting $2.48. The company had a trading volume of 218,821 shares. Trevena has a one year low of $2.15 and a one year high of $8.00. The company’s 50 day moving average price is $2.56 and its 200-day moving average price is $3.80. The company’s market cap is $144.59 million.
Trevena (NASDAQ:TRVN) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.35). Equities research analysts anticipate that Trevena will post ($1.46) EPS for the current fiscal year.
WARNING: This news story was posted by Daily Political and is the property of of Daily Political. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/04/trevenas-trvn-buy-rating-reiterated-at-cowen-and-company.html.
Hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC increased its position in shares of Trevena by 4.5% in the first quarter. FMR LLC now owns 7,037,804 shares of the biopharmaceutical company’s stock worth $25,828,000 after buying an additional 304,256 shares during the period. Citizens & Northern Corp increased its position in shares of Trevena by 87.2% in the first quarter. Citizens & Northern Corp now owns 54,300 shares of the biopharmaceutical company’s stock worth $199,000 after buying an additional 25,300 shares during the period. Piermont Capital Management Inc. increased its position in shares of Trevena by 18.8% in the first quarter. Piermont Capital Management Inc. now owns 91,290 shares of the biopharmaceutical company’s stock worth $335,000 after buying an additional 14,420 shares during the period. Sphera Funds Management LTD. purchased a new position in shares of Trevena during the first quarter worth approximately $429,000. Finally, American International Group Inc. increased its position in shares of Trevena by 7.1% in the first quarter. American International Group Inc. now owns 27,541 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 1,816 shares during the period. Institutional investors and hedge funds own 64.38% of the company’s stock.
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.